Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance
Filings
40 filings of SYNGENE since January 2025.
board outcome 13, presentation 10, transcript 8, results 4, acquisition 4, dividend 1
| Filed | Type | Subject | |
|---|---|---|---|
| 02 Nov 2026 | transcript | Syngene International Limited has informed the Exchange about TranscriptAI summarySyngene International intimated under Regulation 30 the uploading of the transcript of its Q2 FY2027 earnings conference call, held on October 28, 2026, on the company website. The transcript is available at syngeneintl.com under Financial Information, FY 2027, Q2, IR Call Transcript. The filing itself contains no financial figures or management commentary in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Oct 2026 | presentation Results | Syngene International Limited has informed the Exchange about Investor PresentationAI summarySyngene International filed its investor presentation for the quarter and half year ended September 30, 2026 (Q2 FY27), under Regulation 30 of the SEBI LODR Regulations. Q2 FY27 revenue from operations was Rs 833 Cr, up 13% quarter-on-quarter and down 9% year-on-year; H1 FY27 revenue was Rs 1,569 Cr, down 12% year-on-year. Q2 FY27 operating EBITDA margin was 18% (12% in Q1 FY27, 22% in Q2 FY26); management said this reflected lower revenues and forex hedge losses, and that adjusted for the forex hedge loss the margin would be in the mid-20s range. Q2 FY27 PAT before exceptional items was Rs 38 Cr and after exceptional items was Rs 32 Cr, versus Rs 67 Cr in Q2 FY26; exceptional items relate to employee termination benefits. Management said it signed its first manufacturing agreement for the Bayview biologics facility with a large pharmaceutical customer, with process development to begin in India this year and drug-substance manufacturing at Bayview next year. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Oct 2026 | board outcome Results | Syngene International Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.AI summaryBoard of Syngene International approved unaudited standalone and consolidated Ind-AS financial results for the quarter and half year ended September 30, 2026, on October 27, 2026; Limited Review Reports enclosed; meeting ran 15:15 to 18:30 IST. Consolidated revenue from operations for the quarter ended September 30, 2026 was Rs. 8,327 million, versus Rs. 7,360 million in the preceding quarter (June 30, 2026) and Rs. 9,106 million in the corresponding quarter last year. Consolidated profit for the quarter ended September 30, 2026 was Rs. 322 million, versus a loss of Rs. (90) million in the preceding quarter and Rs. 671 million in the corresponding quarter last year. Consolidated revenue from operations for the half year ended September 30, 2026 was Rs. 15,687 million, against Rs. 17,851 million in the half year ended September 30, 2025; half-year profit was Rs. 232 million, against Rs. 1,538 million. Basic EPS for the quarter ended September 30, 2026 was Rs. 0.80 (not annualised). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 24 Aug 2026 | acquisition Acquisition | Syngene International Limited has informed the Exchange about AcquisitionAI summarySyngene International Limited intimated an investment in Ampin C&I Power Twelve Private Limited under a Share Subscription and Shareholders Agreement and Power Purchase Agreement, for acquisition of renewable power. The Company will invest INR 2,52,00,000 in cash for 25,20,000 equity shares of AMPIN at INR 10 per share, to hold 12.44% (undiluted) of AMPIN's paid-up capital. Post further investments by other entities, the Company's stake will be maintained at a minimum of 7.93% (fully diluted), per the agreements. Allotment of shares is expected in one or more tranches within 30 days or another mutually agreed date. No governmental or regulatory approvals are required, per the filing. AMPIN was incorporated on 23 April 2025, is in renewable energy generation, had nil turnover for FY 2025-26 and net worth of Rs. 687.70 lakhs as on 31.03.2026. The filing states the deal is not a related party transaction and no promoter or group company has an interest in AMPIN. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Aug 2026 | transcript | Syngene International Limited has informed the Exchange about TranscriptAI summarySyngene International filed an intimation under Regulation 30 of the SEBI LODR Regulations, 2015, enclosing the web link to the transcript of its Q1 FY2027 earnings conference call. The earnings conference call was held on July 30, 2026, and the transcript is uploaded on the company's website. The filing itself contains no financial figures or management commentary; the transcript content is not included in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jul 2026 | presentation Guidance, Management change, Results | Syngene International Limited has informed the Exchange about Investor PresentationAI summarySyngene filed its Q1 FY27 investor presentation (quarter ended June 30, 2026) under Regulation 30 of SEBI LODR. Revenue from operations was Rs 736 Cr, down 16% Y-o-Y; operating EBITDA margin was 12% versus 24% in Q1 FY26. PAT before exceptional items was Rs 1 Cr; PAT after exceptional items was Rs -9 Cr, after Rs 10 Cr (net of tax) of termination benefits under exceptional items. Management said the quarter was mainly hit by lack of offtake from a major LMCDMO client and a forex hedge loss, and expects a degrowth in the first half of FY27, with single-digit rupee revenue degrowth and mid-20s EBITDA margins for the full year. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jul 2026 | board outcome Dividend / buy-back, Results | Syngene International Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.AI summaryBoard of Directors approved the unaudited standalone and consolidated Ind-AS financial results for the quarter ended June 30, 2026 at a meeting held July 29, 2026 (concluded 3:31 pm IST). Consolidated Q1 FY27 revenue from operations was Rs. 7,360 million, against Rs. 8,745 million in the corresponding quarter last year and Rs. 10,365 million in the preceding quarter (March 2026). Consolidated Q1 FY27 profit for the period was a loss of Rs. 90 million, against a profit of Rs. 867 million a year earlier; basic EPS was Rs. (0.22). Standalone Q1 FY27 revenue from operations was Rs. 6,630 million, with a loss of Rs. 21 million for the period; exceptional items were a net loss of Rs. 135 million, mainly termination benefits. The Board recommended a final dividend of Rs. 1.25 per equity share of Rs. 10, subject to shareholder approval at the AGM. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 May 2026 | board outcome Acquisition | Syngene International Limited has informed the Exchange regarding Outcome of Board Meeting held on May 18, 2026, regarding Voluntary liquidation of Syngene Manufacturing Solutions Limited, a Wholly Owned Subsidiary.AI summaryBoard of Syngene International approved, in principle, the voluntary liquidation of its wholly owned subsidiary Syngene Manufacturing Solutions Limited (SMSL), which is not a material subsidiary and has no business operations. SMSL contributed nil turnover (0.00%) and net worth of Rs. 93,97,513 (0.02%) for the financial year ended March 31, 2026. Closure is expected under the IBC 2016 and IBBI voluntary liquidation regulations, subject to SMSL shareholder approval and other regulatory approvals, if any. The company stated the liquidation will not affect any business or have a material impact on consolidated financials. The board meeting was held on May 18, 2026, from 21:05 to 22:00 (IST). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 May 2026 | transcript | Syngene International Limited has informed the Exchange about TranscriptAI summarySyngene International Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations, 2015, giving the web link to the transcript of its Q4 FY2026 earnings call. The earnings call was held on April 30, 2026. The transcript is uploaded on the company's website at syngeneintl.com. The filing itself contains no financial figures or management commentary. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Apr 2026 | presentation Capex, Management change, Results | Syngene International Limited has informed the Exchange about Investor PresentationAI summaryInvestor presentation for the quarter and year ended March 31, 2026, filed under Regulation 30, to be used for meetings with analysts and institutional investors. Q4 FY26 revenue from operations was Rs 1,037 Cr (2% Y-o-Y, about USD 112 Mn), with operating EBITDA margin of 29% (34% in Q4 FY25) and PAT before exceptional items of Rs 153 Cr (down 16% YoY). FY26 revenue from operations was Rs 3,739 Cr (3% Y-o-Y, about USD 419 Mn), with operating EBITDA margin of 25% (29% in FY25) and PAT before exceptional items of Rs 380 Cr (down 20% YoY). Management reported commencement of operations at the ADC discovery laboratory, completion of 14 audits in the quarter (85 in FY26), and GCP-NABL accreditation. Management announced Kiran Mazumdar-Shaw as Executive Chairperson from April 1, 2026, and Siddharth Mittal as Managing Director & CEO effective July 1, 2026, succeeding Peter Bains. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Apr 2026 | dividend Acquisition, Dividend / buy-back, Management change, Results | Syngene International Limited has informed the Exchange that Board of Directors at its meeting held on April 29, 2026, recommended Final Dividend of Rs. 1.25 per equity share.AI summaryBoard of Syngene International approved audited standalone and consolidated results for the quarter and year ended March 31, 2026. Standalone FY2026 revenue from operations was Rs. 34,238 million and profit for the year was Rs. 3,049 million; Q4 FY2026 standalone profit was Rs. 1,482 million. Consolidated FY2026 revenue from operations was Rs. 37,387 million and profit for the year was Rs. 3,167 million; Q4 FY2026 consolidated profit was Rs. 1,479 million. Board recommended a final dividend of Re. 1.25 per equity share of Rs. 10 for FY2025-26, with record date June 26, 2026. Board approved appointment of S. R. Batliboi & Associates LLP as statutory auditors for 5 years from the 33rd AGM, and fixed the 33rd AGM for July 29, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Apr 2026 | board outcome Dividend / buy-back, Guidance, Management change, Results | Syngene International Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summarySyngene International's board approved audited standalone and consolidated results for the quarter and year ended March 31, 2026. Consolidated revenue from operations for Q4 FY26 was Rs. 10,365 million; consolidated profit for the period was Rs. 1,479 million, against Rs. 1,833 million a year earlier. Consolidated revenue from operations for FY26 was Rs. 37,387 million; consolidated profit for the year was Rs. 3,167 million. The board recommended a final dividend of Re. 1.25 per equity share of Rs. 10 for FY2025-26, with record date June 26, 2026. The board approved S. R. Batliboi & Associates LLP as statutory auditors for five years from the 33rd AGM (to be held July 29, 2026), subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jan 2026 | transcript | Syngene International Limited has informed the Exchange about TranscriptAI summarySyngene International filed an intimation dated January 29, 2026 under Regulation 30 of the SEBI LODR Regulations, 2015. The filing gives the web link for the transcript of the Q3 FY2026 earnings call held on January 23, 2026. The transcript has been uploaded on the company's website; the filing itself does not contain the call's financial figures or management commentary. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Jan 2026 | presentation Capex, Dividend / buy-back, Results | Syngene International Limited has informed the Exchange about Investor PresentationAI summarySyngene International filed its investor presentation for the quarter and nine months ended December 31, 2025 (Q3 FY26 and 9M FY26), under Regulation 30 of the SEBI LODR Regulations. Q3 FY26 revenue from operations was Rs 917 Cr (down 3% Y-o-Y, about USD 103 Mn), with operating EBITDA margin of 23% (30% in Q3 FY25) and reported PAT before exceptional items of Rs 73 Cr (down 44% Y-o-Y). 9M FY26 revenue from operations was Rs 2,702 Cr (up 3% Y-o-Y, about USD 307 Mn), with operating EBITDA margin of 23% (27% in 9M FY25) and reported PAT before exceptional items of Rs 227 Cr (down 22% Y-o-Y). Management highlighted that Bristol Myers Squibb extended its partnership with Syngene through 2035, and that the company commissioned a new commercial-scale facility for liquid-filled hard gelatin capsules. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 22 Jan 2026 | board outcome Acquisition, Capex, Results | Syngene International Limited has informed the Exchange regarding Board meeting held on January 22, 2026.AI summarySyngene International filed the outcome of its board meeting held on January 22, 2026, approving unaudited standalone and consolidated Ind AS results for the quarter and nine months ended December 31, 2025. Consolidated revenue from operations for the quarter ended December 31, 2025 was Rs. 9,171 million (OCR figure, may be imprecise); standalone revenue from operations was Rs. 8,344 million. Labour Code impact of Rs. 706 million (consolidated) and Rs. 658 million (standalone), mainly gratuity from a change in wage definition, was shown under exceptional items for the quarter. Note 6 records that Syngene USA acquired a biologics site in the USA; pre-operating costs of Rs. 304 million were added to capital work in progress in the nine months ended December 31, 2025. The filing does not contain management commentary on the business outlook. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 22 Jan 2026 | board outcome Legal, Results | Syngene International Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.AI summarySyngene International Limited's board approved the unaudited standalone and consolidated Ind AS financial results for the quarter and nine months ended December 31, 2025 at its meeting held on January 22, 2026. Standalone revenue from operations was Rs. 8,344 million for the quarter ended December 31, 2025 (Rs. 8,771 million in the corresponding prior-year quarter), and Rs. 24,638 million for the nine months. Consolidated revenue from operations was Rs. 9,171 million for the quarter ended December 31, 2025 (Rs. 9,106 million in the September 2025 quarter in the printed comparatives, text partly garbled). Exceptional items of Rs. 658 million (standalone) and Rs. 706 million (consolidated) were recorded for the quarter and nine months, mainly gratuity impact from the new Labour Codes notified on November 21, 2025. The filing is a routine results submission with limited review reports from the statutory auditor, which are unqualified. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Dec 2025 | acquisition Acquisition, Capex | Syngene International Limited has informed the Exchange about AcquisitionAI summarySyngene International intimated an investment of Rs. 35 Mn in O2 Renewable Energy V Private Limited (O2 RE V), revised from its earlier plan involving O2 Renewable Energy II Private Limited. The company entered into a Power Purchase Agreement and Share Purchase Agreement to source renewable power from O2 RE V, citing regulatory changes affecting solar power and longer infrastructure setup time for wind energy in O2 RE II. Syngene will acquire 8.23% stake, for cash consideration of Rs. 35,000,000, from Dalmia Cement (Bharat) Limited in one or more tranches on or before March 31, 2026. Along with other captive investors, Syngene will hold a minimum 26% stake in O2 RE V for the term of the PPA to maintain captive status. O2 RE V's turnover was Rs. 20,29,37,390 in FY 2024-25 and Rs. 26,05,28,600 in FY 2023-24. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 Dec 2025 | presentation | Syngene International Limited has informed the Exchange about Investor PresentationAI summarySyngene International filed an investor presentation dated December 17, 2025, to be shared with investors and analysts at a meeting held the same day. The presentation is a webinar on the clinical trials market, presented by Dr. Mrinal Kammili, Head of Translational & Clinical Research. Management said Syngene announced in Q2 FY26 a deal for a first global phase III clinical trial from a U.S.-based biotech company, with patients recruited across sites in India and the U.S. Management cited the global CRDMO market expected to grow at about 9% CAGR, and the clinical CRO market growing at double digits, driven by R&D pipelines, patient diversity needs, APAC cost advantages and big pharma outsourcing. Participants were asked not to ask questions on specific Syngene financials. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Nov 2025 | transcript | Syngene International Limited has informed the Exchange about TranscriptAI summarySyngene International intimated to BSE and NSE the earnings call transcript for Q2 FY2026, held on November 06, 2025. The transcript has been uploaded on the company's website; the filing gives the web link to it. The filing itself contains no financial figures or management commentary. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Nov 2025 | presentation Capex, Legal, Results | Syngene International Limited has informed the Exchange about Investor PresentationAI summarySyngene International filed its investor presentation for the quarter and half year ended September 30, 2025 (Q2 FY26 and H1 FY26), to be used for meetings with analysts or institutional investors. Q2 FY26 revenue from operations was Rs 911 Cr (2% Y-o-Y, about USD 103 Mn), with operating EBITDA margin of 22% (27% in Q2 FY25) and reported PAT before exceptional items down 37% YoY. H1 FY26 revenue from operations was Rs 1,785 Cr (6% Y-o-Y, about USD 204 Mn), with operating EBITDA margin of 23% (25% in H1 FY25) and reported PAT before exceptional items down 4% YoY. The company said it secured its first global phase III clinical trial from a U.S.-based biotech company and expanded its clinical trials footprint to Australia, New Zealand, the UK, Sri Lanka and Eastern Europe. The company said it will add a GMP bioconjugation suite to its Bengaluru biologics facility, and that the Bayview biologics facility in the U.S. is on track for operationalization in the second half of the year. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Nov 2025 | board outcome Results | Syngene International Limited has informed the Exchange regarding Board meeting held on November 05, 2025.AI summarySyngene International filed the outcome of its board meeting held November 5, 2025, approving unaudited standalone and consolidated Ind-AS results for the quarter and half year ended September 30, 2025. Standalone revenue from operations for the quarter ended September 30, 2025 was Rs. 8,301 million, against Rs. 8,213 million in the corresponding quarter of the prior year (figures as legible in the scanned text). Consolidated revenue from operations for the quarter was Rs. 8,745 million (as legible in the scanned text). Standalone basic EPS for the quarter was Rs. 1.65 (not annualised), and consolidated basic EPS was Rs. 3.04 (not annualised) per the scanned text. The board meeting ran from 02:15 pm to 07:43 pm (IST); the results were filed with Limited Review Reports. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Nov 2025 | board outcome Results | Syngene International Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.AI summarySyngene International filed the outcome of its board meeting held November 5, 2025, approving unaudited standalone and consolidated Ind-AS results for the quarter and half year ended September 30, 2025. Standalone revenue from operations for the quarter ended September 30, 2025 was Rs. 8,301 million; the filing shows standalone total income and profit figures, with basic EPS of Rs. 1.65 for the quarter (not annualised). Consolidated basic EPS for the quarter was Rs. 3.05 (not annualised) per the consolidated statement; the consolidated revenue from operations for the quarter was Rs. 8,745 million per the OCR text. Paid-up equity share capital was Rs. 4,029 million (face value Rs. 10 per share) as at September 30, 2025. The board meeting commenced at 2:15 pm IST and concluded at 7:43 pm IST; the results are also available on the company website. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 09 Sep 2025 | presentation Acquisition, Capex, Guidance, Legal | Syngene International Limited has informed the Exchange about Investor PresentationAI summarySyngene International filed an investor presentation dated September 9, 2025, for a Unit-3 plant visit and Q&A meeting with investors and analysts held the same day. The Unit-3 biologics facility was acquired from Stelis Biopharma in December 2023 for Rs 617 crores (USD 75 million), funded through internal accruals and cash, and adds 20 KL of biologics drug substance capacity with potential expansion of a further 20 KL. Management said the acquisition guidance is being maintained: $10 million modification capex, $85 million total to operationalise, asset turnover of 1x in less than 5 years, minor short-term dilution of operating margins, EBITDA margins in line with company average from FY29, and positive PAT contribution from FY27. Management said part of Unit-3 became operational in Q1 FY26, with one of two lines in drug substance (8 KL, 4 x 2 KL commissioned) and local regulatory approvals received in May 2025. Management said it delivered a GMP clinical batch of drug substance for a US-based client in Q1 FY26 and is focused on building an integrated human and animal health pipeline. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jul 2025 | transcript | Syngene International Limited has informed the Exchange about TranscriptAI summarySyngene International filed an intimation on July 29, 2025 of the earnings call transcript for Q1 FY2026. The earnings call was held on July 24, 2025. The transcript has been uploaded to the company's website, and the filing gives the web link. The filing itself contains no financial figures or management commentary. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 24 Jul 2025 | presentation Legal, Results | Syngene International Limited has informed the Exchange about Investor PresentationAI summarySyngene International filed its investor presentation for the quarter ended June 30, 2025 (Q1 FY26) under Regulation 30, to be used for meetings with analysts or institutional investors. Q1 FY26 revenue from operations was Rs 875 Cr, up 11% year-on-year (about USD 102 Mn at about INR 86 per USD). Operating EBITDA margin was 23.6%, compared with 21.5% in Q1 FY25. Reported PAT before exceptional items was Rs 87 Cr, up 59% year-on-year. Management highlighted a successful USFDA GCP inspection of its Human Pharmacology Unit with no observations, and a favorable VAI outcome for the Biologics facility at Biocon Park after an EIR. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Jul 2025 | board outcome Capex, Dividend / buy-back, Results | Syngene International Limited has informed the Exchange regarding Board meeting held on July 23, 2025.AI summarySyngene International filed the outcome of its board meeting held on 23 July 2025, approving unaudited standalone and consolidated Ind-AS results for the quarter ended 30 June 2025. Consolidated total income for Q1 FY26 was Rs 8,922 million, against Rs 8,078 million in the corresponding quarter of the previous year, and consolidated profit for the period was Rs 867 million, against Rs 757 million. Standalone revenue from operations was Rs 7,993 million, against Rs 7,265 million a year earlier, and standalone profit for the period was Rs 740 million, against Rs 739 million. The board recommended a final dividend of Rs 1.25 per equity share of Rs 10, subject to shareholder approval at the AGM; this recommendation was noted in the filing's notes as made on 23 April 2025. The filing states the quarter included a license grant and capitalisation of Rs 3,438 million of a drug substance production line and related depreciation of Rs 36 million. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Jul 2025 | board outcome Dividend / buy-back, Results | Syngene International Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summarySyngene International Limited's board approved the unaudited standalone and consolidated Ind-AS financial results for the quarter ended June 30, 2025, on July 23, 2025. Consolidated revenue from operations for Q1 FY26 was Rs 8,745 million, against Rs 7,897 million in the corresponding quarter of the previous year and Rs 10,180 million in the preceding quarter. Consolidated profit for the period was Rs 867 million, against Rs 757 million a year earlier; consolidated basic EPS was Rs 2.16 (not annualised). Standalone revenue from operations was Rs 7,993 million and standalone profit for the period was Rs 740 million for the quarter. The board recommended a final dividend of Rs 1.25 per equity share, subject to shareholder approval at the AGM. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Apr 2025 | transcript | Syngene International Limited has informed the Exchange about TranscriptAI summarySyngene International Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations, 2015, giving the web link to the transcript of its Q4 FY2025 earnings call. The earnings call was held on April 24, 2025, and the transcript has been uploaded to the company's website. The filing contains only the link and the transcript's date; it does not state management's remarks or any financial figures. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 24 Apr 2025 | board outcome Dividend / buy-back, Legal, Management change, Results | Syngene International Limited has informed the Exchange regarding Outcome of Board Meeting held on April 23, 2025.AI summaryBoard of Syngene International approved audited standalone and consolidated Ind-AS results for the quarter and year ended March 31, 2025, filed with the exchanges on April 23, 2025. Standalone revenue from operations for FY2025 was Rs. 33,733 million versus Rs. 32,031 million in FY2024; consolidated revenue from operations for FY2025 was Rs. 36,424 million. Board recommended a final dividend of Re. 1.25 per equity share of Rs. 10 for FY2024-25, with record date June 27, 2025. Board approved appointment of V Sreedharan & Associates as Secretarial Auditors for five years from the 2025 AGM, subject to shareholder approval. Board approved convening the 32nd AGM on July 23, 2025, and approved an increase in MD & CEO Peter Bains' remuneration limit (up to 7% of net profits, subject to shareholder approval). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Apr 2025 | board outcome Dividend / buy-back, Legal, Management change, Results | Syngene International Limited has informed the Exchange regarding Board meeting held on April 23, 2025.AI summaryBoard of Syngene International approved audited standalone and consolidated Ind-AS financial results for the quarter and year ended March 31, 2025. Board recommended a final dividend of Re.1.25 per equity share of Rs.10 for FY 2024-25, with record date Friday, June 27, 2025. Board approved appointment of V Sreedharan & Associates as Secretarial Auditors for five consecutive years from the 2025 AGM, subject to shareholder approval. Board approved convening the 32nd Annual General Meeting on Wednesday, July 23, 2025. Board approved an increase in Managing Director & CEO Peter Bains' managerial remuneration above the prescribed limit (not exceeding 7% of net profits), and amendments to the LTIP 2023 and termination of the RSU Plan FY 2020, all subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 24 Mar 2025 | acquisition Acquisition | Syngene International Limited has informed the Exchange about AcquisitionAI summarySyngene International Limited filed an intimation under Regulation 30 of SEBI Listing Regulations about an investment in O2 Renewable Energy II Private Limited. The company entered into an amendment to its Share Subscription/Purchase and Shareholders Agreement with O2 for acquisition of renewable power; the stake is to be at least 26% throughout the term of the Power Purchase Agreement. Consideration is cash of Rs. 65,000,000 (Rs. 6.5 crore); Syngene's stake in O2 increases to 33.79%. Subscription of equity shares and Compulsory Convertible Debentures is to be completed in one or more tranches on or before May 31, 2025, or another mutually agreed date. O2 is engaged in power generation from a 201.2 MW wind-solar hybrid plant in Karnataka; its FY 2023-24 turnover was Rs. 5,12,38,770. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 Mar 2025 | results Results | The Exchange had sought clarification from Syngene International Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the AI summarySyngene International Limited wrote to NSE on March 14, 2025, replying to NSE's email of March 5, 2025 seeking clarification on its financial results. The company clarified that the figures in its results for the quarter and nine months ended December 31, 2024 are in INR Millions, except per-share data. The company states it had already made this clarification in the Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024, filed on January 23, 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Mar 2025 | presentation Acquisition, Capex, Guidance, Results | Syngene International Limited has informed the Exchange about Investor PresentationAI summarySyngene International filed an investor presentation shared with investors and analysts at its investor meet held on March 12, 2025, referencing an earlier intimation dated March 7, 2025. The presentation shows revenue from operations rising from INR 14,231 mn in FY18 to INR 34,886 mn in FY21 and INR 50,239 mn in FY24, with PAT (before exceptional items) of INR 5,186 mn in FY24. Management said the company has more than doubled its qualified infrastructure since FY16, has 400+ clients including 14 of the top 20 pharma companies, and has expanded into commercial biologics manufacturing with Zoetis. Management said the global CRDMO market is expected to grow at 6% to 8% a year, with subdued growth in the next two years, and that the company is focusing on new modalities, talent, productivity and a global footprint, including a US biologics facility. The company stated that no additional information was disclosed beyond what was already in the public domain. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Mar 2025 | acquisition Acquisition, Capex | Syngene International Limited has informed the Exchange about AcquisitionAI summarySyngene International Limited filed under Regulation 30 that it will make an additional investment of up to USD 56 million in equity share capital of its wholly owned subsidiary Syngene USA Inc (SUSA), in one or more tranches. The investment will finance the acquisition of a biologics facility from Emergent Manufacturing Operations Baltimore, LLC, and general corporate and day-to-day operating requirements. The transaction is cash consideration, is between holding company and wholly owned subsidiary (not a related party transaction), and the company's shareholding in SUSA will not change. Completion is expected on or before March 31, 2026, or another date mutually agreed. SUSA's turnover was USD 7,332,492 in FY 2023-24, USD 5,517,593 in FY 2022-23 and USD 3,752,450 in FY 2021-22. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Mar 2025 | results | The Exchange has sought clarification from Syngene International Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the | |
| 28 Jan 2025 | transcript | Syngene International Limited has informed the Exchange about TranscriptAI summarySyngene International Limited filed an intimation of the earnings call transcript for Q3 FY2025, with the transcript link on the company website. The Q3 FY2025 earnings call was conducted on January 23, 2025. The investor presentation was submitted to the stock exchanges and uploaded to the website on January 23, 2025. The filing contains no financial figures or management commentary on the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Jan 2025 | results Results | Integrated Filing (Financials) for the quarter and nine months ended December 31, 2024AI summarySyngene International filed its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, approved by the Board on January 23, 2025 (figures in INR millions except per share data). Consolidated revenue from operations was 9,437 for the quarter ended December 31, 2024 versus 8,535 a year earlier, and 26,244 for nine months versus 25,717 a year earlier. Consolidated profit for the period was 1,311 for the quarter versus 1,115 a year earlier, and 3,129 for nine months versus 3,214 a year earlier. Consolidated basic EPS was 3.27 for the quarter (not annualised) versus 2.78 a year earlier. Standalone revenue from operations was 8,xxx for the quarter (figure partly illegible in the filing text), and standalone profit for the quarter was 1,231. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Jan 2025 | presentation Results | Syngene International Limited has informed the Exchange about Investor PresentationAI summarySyngene International filed its investor presentation for the quarter and nine months ended December 31, 2024 (Q3 and 9M FY25), under Regulation 30 of the SEBI LODR Regulations. Q3 FY25 revenue from operations was Rs 944 Crs, up 11% YoY (about USD 111 Mn at about INR 85 per USD); operating EBITDA margin was 30% versus 27% in Q3 FY24. Q3 FY25 PAT before exceptional items was Rs 131 Crs, up 14% YoY; PAT after exceptional items was Rs 131 Crs, up 18% YoY. 9M FY25 revenue from operations was Rs 2,624 Crs, up 2% YoY; operating EBITDA margin was 27%, same as 9M FY24. 9M FY25 PAT before exceptional items was Rs 292 Crs, down 12% YoY; PAT after exceptional items was Rs 313 Crs, down 3% YoY. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Jan 2025 | results Results | Syngene International Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.AI summaryBoard of Syngene International approved unaudited standalone and consolidated Ind-AS results for the quarter and nine months ended December 31, 2024, on January 23, 2025. Consolidated revenue from operations for the quarter ended December 31, 2024 was Rs 9,437 million, against Rs 8,535 million a year earlier. Consolidated profit for the period was Rs 1,311 million for the quarter, against Rs 1,115 million a year earlier. Standalone revenue from operations for the quarter was Rs 8,811 million (the OCR of this figure is uncertain), against Rs 7,919 million a year earlier. Consolidated basic EPS for the quarter was Rs 3.27 (not annualised), against Rs 2.78 a year earlier. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Jan 2025 | board outcome Results | Syngene International Limited has informed the Exchange regarding Board meeting held on January 23, 2025.AI summarySyngene International's board approved the unaudited standalone and consolidated Ind-AS results for the quarter and nine months ended December 31, 2024, on January 23, 2025. Consolidated revenue from operations for Q3 FY25 was Rs 9,437 million, against Rs 8,535 million in the corresponding quarter last year; consolidated net profit for the quarter was Rs 1,311 million. Standalone revenue from operations for the quarter was Rs 8,811 million (text partly unclear in scan), and standalone profit for the period was Rs 1,231 million. Consolidated basic EPS for the quarter was Rs 3.27 (not annualised), against Rs 2.78 a year earlier. The statutory auditor's limited review reports on the results are unqualified. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.